Latest Investment Will Support the Democratization of Precision Medicine Through the Advancement of Novel Explainable AI Algorithms
Zephyr AI, Inc. (Zephyr AI), a healthcare technology company committed to developing fast and explainable Artificial Intelligence (AI)…
What You Should Know: – Zephyr AI, a healthcare technology company pioneering explainable AI (XAI) for precision medicine, raises $111M in Series A round led by Revolution Growth, Eli Lilly & Company, Jeff Skoll,…
Continue Reading
What You Should Know:
– Eli Lilly and Company (Lilly) and Amazon Pharmacy today announced a strategic collaboration to improve patient access to GLP-1 medications for diabetes, obesity, and migraines.
– The partnership aims to improve…
Continue Reading
Eli Lilly and Company has added Amazon Pharmacy as a third-party dispensing provider for LillyDirect Pharmacy Solutions, meaning the company will provide home delivery services for certain medications through LillyDirect, the companies announced Wednesday.
LillyDirect,…
The direct-to-consumer (DTC) model of healthcare may be the future of healthcare delivery in regards to consumer access and potentially reducing bureaucracy. Even Eli Lilly is getting in on the action with LillyDirect for…
Continue Reading
What You Should Know:
– Eli Lilly and Company (NYSE: LLY) announced today the launch of LillyDirect™, a comprehensive digital healthcare platform designed to empower patients living with obesity, migraine, and diabetes in the U.S….
Continue Reading
What You Should Know: Yseop, a world-leading Generative AI company for life sciences, today announces the closing of a strategic investment round, with new investor Novartis (dRx Capital), joining existing investors Eli Lilly, NextStage…
Continue Reading
A study conducted by The University of Texas MD Anderson Cancer Center recommends intensity-modulated radiation therapy (IMRT) as the preferred treatment for locally advanced non-small cell lung cancer (NSCLC). IMRT significantly reduces lung and…
Continue Reading
by Fred Pennic 07/14/2023 Leave a Comment
Versanis logo
What You Should Know:
Eli Lilly announced an agreement to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of…
Continue Reading
Eli Lilly’s experimental obesity drug, retatrutide, has shown impressive results in mid-stage clinical trials, with patients experiencing up to 24% weight loss after almost a year, the highest reduction seen in the field. The…
Continue Reading
